This anti-FLT3 antibody is a Mouse Monoclonal antibody detecting FLT3 in FACS. Suitable for Human. This Primary Antibody has been cited in 1 publication.
The mouse monoclonal antibody BV10A4 (BV10) reacts with an extracellular epitope of CD135 (FLT3, FLK2, STK-1), a 130-160 kDa type I transmembrane receptor tyrosine kinase that is involved in early steps of hematopoiesis.
No Cross-Reactivity
Mouse
Cross-Reactivity (Details)
Human
Purification
Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
FLT3
Reactivity: Human
FACS
Host: Mouse
Monoclonal
BV10A4
PE
Application Notes
Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μL reagent / 100 μL of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C
Storage Comment
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Haylock, Horsfall, Dowse, Ramshaw, Niutta, Protopsaltis, Peng, Burrell, Rappold, Buhring, Simmons: "Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand." in: Blood, Vol. 90, Issue 6, pp. 2260-72, (1997) (PubMed).
Target
FLT3
(Fms-Related tyrosine Kinase 3 (FLT3))
Alternative Name
CD135
Background
Fms related tyrosine kinase 3,CD135 / FLT3, also known as FLK2 or STK-1 is a receptor tyrosine kinase that plays important roles in hematopoiesis. After binding of Flt3 ligand (FL), CD135 homodimerizes and stimulates proliferation, differentiation and protects the cell from apoptosis. The loss of CD90 and gain of CD135 expression marks the loss of self-renewal in hematopoietic stem cell population. Detectable CD135 expression appears first at low levels on the surface of primitive multilineage progenitor cells and disappears during defined stages of B-cell development, but is upregulated and maintained during maturation of monocytes. CD135 is also expressed on thymocytes, dendritic cell progenitors and on mature dendritic cells, as well as on various malignant hematopoietic cells.,FLT3, FLK2, STK1